Characterizing neuroanatomical markers of different stages of schizophrenia (SZ) to assess
pathophysiological models of how the disorder develops is an important target for the …

Introduction A staging model is a clinical tool used to define the development of a disease
over time. In schizophrenia, authors have proposed different theoretical staging models of …

Objective: Determining the extent to which relationships between duration of untreated
psychosis (DUP) and outcome endure longitudinally across the lifetime course of psychotic …

This is a report of a joint World Psychiatric Association/International College of
Neuropsychopharmacology (WPA/CINP) workgroup concerning the risk/benefit ratio of …

Background This study aimed to examine the relationships among cognitive function,
symptoms, prefrontal activation, basic driving skills, and collision risk factors using a hazard …

Background Difficulties in the ability to adapt beliefs in the face of new information are
associated with psychosis and its central symptom–paranoia. As cognitive processes and …

Examining the heterogeneity of negative symptoms of schizophrenia contributes to the
identification of available treatment targets. Generally, prior evidence classified three to four …

Background The aim of the post hoc analysis was to better understand the efficacy and
safety of cariprazine in patients with schizophrenia for less than 5 years (early stage) and for …

Schizophrenia is a complex and heterogenous psychiatric disorder. This study aimed to
demonstrate the potential of circulating microRNAs (miRNAs) as a clinical biomarker to …

Objective This scientific research aimed to investigate the feasibility of implementing a
clinical staging (CS) model for personality disorders (PDs) in older adults. The CS model …